Seattle Genetics, Inc. (SGEN) Reaches $49.26 After 3.00% Down Move; GERRY WEBBER INTERNATIONAL AG ORDINARY S (GRYIF) Shorts Lowered By 22.4%

April 24, 2018 - By Richard Conner

Seattle Genetics, Inc. (NASDAQ:SGEN) Logo

GERRY WEBBER INTERNATIONAL AG ORDINARY S (OTCMKTS:GRYIF) had a decrease of 22.4% in short interest. GRYIF’s SI was 64,800 shares in April as released by FINRA. Its down 22.4% from 83,500 shares previously. It closed at $10.7 lastly. It is down 0.00% since April 24, 2017 and is . It has underperformed by 11.55% the S&P500.

The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) is a huge mover today! The stock decreased 1.09% or $0.544 during the last trading session, reaching $49.256. About 408,280 shares traded. Seattle Genetics, Inc. (NASDAQ:SGEN) has declined 20.48% since April 24, 2017 and is downtrending. It has underperformed by 32.03% the S&P500.The move comes after 6 months negative chart setup for the $7.79 billion company. It was reported on Apr, 24 by Barchart.com. We have $47.78 PT which if reached, will make NASDAQ:SGEN worth $233.70M less.

GERRY WEBER International AG operates as a fashion and lifestyle company. The company has market cap of $. It operates through Wholesale, Retail, and HALLHUBER divisions. It currently has negative earnings. The firm engages in the design, production, wholesale, and retail of ladies wear products.

Investors sentiment increased to 1.23 in 2017 Q4. Its up 0.45, from 0.78 in 2017Q3. It improved, as 24 investors sold Seattle Genetics, Inc. shares while 67 reduced holdings. 44 funds opened positions while 68 raised stakes. 141.83 million shares or 1.14% more from 140.23 million shares in 2017Q3 were reported. Piedmont Inv Advisors Ltd owns 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN) for 9,366 shares. Moreover, Parametric Portfolio Associate Ltd Limited Liability Company has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). 1,000 are held by Clearbridge Investments Llc. Spark Mngmt Limited accumulated 0.31% or 108,000 shares. Verition Fund Mgmt Lc reported 0.02% in Seattle Genetics, Inc. (NASDAQ:SGEN). Vanguard Gp holds 7.78M shares or 0.02% of its portfolio. Grp Incorporated Incorporated holds 2,266 shares or 0% of its portfolio. Rmb Ltd holds 0.07% in Seattle Genetics, Inc. (NASDAQ:SGEN) or 48,284 shares. California State Teachers Retirement Systems owns 155,684 shares. Oregon Public Employees Retirement Fund has 15,171 shares. Tradewinds Capital Mngmt Limited Co holds 0.06% or 2,344 shares. Opus Point Prtnrs Mgmt Limited Liability Corp accumulated 35,668 shares. Dimensional Fund Advisors Lp invested in 0% or 162,950 shares. Prudential, New Jersey-based fund reported 6,091 shares. Qs Investors Lc holds 0% or 3,511 shares.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide. The company has market cap of $7.79 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. It currently has negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

Among 18 analysts covering Seattle Genetics (NASDAQ:SGEN), 9 have Buy rating, 0 Sell and 9 Hold. Therefore 50% are positive. Seattle Genetics had 66 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Hold” rating by J.P. Morgan on Thursday, June 8. Needham maintained the stock with “Buy” rating in Friday, September 15 report. As per Wednesday, November 8, the company rating was initiated by Oppenheimer. RBC Capital Markets maintained it with “Buy” rating and $69.0 target in Monday, November 13 report. The rating was maintained by Cowen & Co on Tuesday, June 6 with “Hold”. The stock of Seattle Genetics, Inc. (NASDAQ:SGEN) earned “Buy” rating by William Blair on Tuesday, August 25. Cowen & Co maintained Seattle Genetics, Inc. (NASDAQ:SGEN) on Thursday, July 27 with “Hold” rating. The firm earned “Neutral” rating on Monday, December 12 by Credit Suisse. As per Wednesday, February 14, the company rating was upgraded by JP Morgan. The rating was maintained by Piper Jaffray on Friday, October 27 with “Hold”.

Since December 11, 2017, it had 1 buying transaction, and 7 sales for $194.17 million activity. SIEGALL CLAY B sold $1.08 million worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Friday, March 9. Another trade for 3.85M shares valued at $200.00 million was made by BAKER BROS. ADVISORS LP on Thursday, February 1. The insider HIMES VAUGHN B sold $290,604. $552,452 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) shares were sold by DRACHMAN JONATHAN G.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Richard Conner

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: